Advertisement

Topics

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

2015-04-08 09:24:45 | BioPortfolio

Published on BioPortfolio: 2015-04-08T09:24:45-0400

Clinical Trials [65 Associated Clinical Trials listed on BioPortfolio]

Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia

SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is ...

The Role of the Muscle-nervous System Interface in Cancer Cachexia

Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which...

Insulin Treatment in Cancer Cachexia

The study is designed to evaluate whether daily insulin treatment to weight losing cancer patients attenuates progression of cancer cachexia and improves metabolism.

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been de...

Regimen for the Treatment of Cachexia in Subjects With NSCLC

Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioni...

PubMed Articles [53 Associated PubMed Articles listed on BioPortfolio]

Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.

Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulati...

A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer.

The semantics of defining cancer cachexia over the last decade has resulted in uncertainty as to the prevalence. This has further hindered the recognition and subsequent treatment of this condition. F...

Cardiac Cachexia - A Window to the Wasting DisordersCardiac cachexia: perspectives for prevention and treatmentSkeletal muscle aging: influence of oxidative stress and physical exerciseCancer-induced muscle wasting: latest findings in prevention and treatmentCancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review)Muscle wasting and cachexia in heart failure: mechanism

Sarcopenia and cachexia evaluation in different healthcare settings: a questionnaire survey of health professionals.

The rates of sarcopenia and cachexia evaluations by different occupational groups at different settings are unclear. The objectives are to evaluate and compare the relative use of sarcopenia and cache...

Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia.

Cancer cachexia is characterized by extreme skeletal muscle loss that results in high morbidity and mortality. The incidence of cachexia varies among tumor types, being lowest in sarcomas, whereas 90%...

Medical and Biotech [MESH] Definitions

General ill health, malnutrition, and weight loss, usually associated with chronic disease.

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)

More From BioPortfolio on "Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial